Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Zeltiq Aesthetics Inc (ZLTQ), MAKO Surgical Corp. (MAKO) & Last Week’s Biggest Winners

What’s better than momentum? Mo’ momentum. Let’s take a closer look at five of this past week’s biggest scorchers.

Company Aug. 2 Weekly Gain
ZELTIQ (NASDAQ:ZLTQ) Aesthetics $8.23 34%
MAKO (NASDAQ:MAKO) Surgical $15.62 25%
Vical (NASDAQ:VICL) $4.81 21%
MercadoLibre (NASDAQ:MELI) $128.37 14%
Facebook (NASDAQ:FB) $38.05 12%

Source: Barron’s.

Let’s start with Zeltiq Aesthetics Inc (NASDAQ:ZLTQ). This is the company behind CoolSculpting, a machine that aims to freeze off the fat from those love handles. It may sound like a flaky idea, but a growing number of dermatologists, cosmetic surgeons, and dieticians have ordered the the machine and continue to use it.

Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) surprised investors with a strong quarterly report, boosting its guidance dramatically for all of 2013. The company now sees revenue growing 20%, up from its earlier outlook of 10%.

MAKO Surgical Corp. (NASDAQ:MAKO)

MAKO Surgical Corp. (NASDAQ:MAKO) also moved higher after well-received financials. Sure, it did post a larger deficit than Wall Street was expecting, but the news on its RIO system was encouraging. MAKO Surgical Corp. (NASDAQ:MAKO)’s revenue rose 19%, but its procedure revenue climbed 26% during the period. In other words, orthopedic surgeons are using the robotic surgical system. Piper Jaffray raised its price target on MAKO Surgical Corp. (NASDAQ:MAKO) from $23 to $26 after the report.

Vical Incorporated (NASDAQ:VICL) posted another quarterly loss on light revenue, but investors aren’t looking at the upstart biotech’s past these days. Vical Incorporated (NASDAQ:VICL) is getting ready to report top-line results from its critical phase 3 study of its Allovectin vaccine’s ability to tackle melanoma.

Mercadolibre Inc (NASDAQ:MELI) moved nicely higher after delivering another strong quarter. The leading online marketplace operator through Latin America saw its revenue grow at a robust 40% clip. That’s caliente! Earnings didn’t grow as quickly, but the $0.67 a share it did earn was well ahead of the $0.62 Wall Street was targeting.

Finally, we have Facebook Inc (NASDAQ:FB) doing something that it hasn’t done in 15 months. The social-networking giant closed above its $38 IPO price on Friday. The only other time that happened was the day Facebook Inc (NASDAQ:FB) went public in May of last year.

Investors continue to hop back on to the dot-com giant after a strong quarterly report a week earlier. Facebook’s strength in monetizing mobile has turned last year’s IPO debacle into this year’s comeback kid.

The article 5 of Last Week’s Biggest Winners originally appeared on and is written by Rick Munarriz.

Longtime Fool contributor Rick Munarriz has no position in any stocks mentioned. The Motley Fool recommends Facebook, MAKO Surgical, and MercadoLibre and owns shares of Facebook and MercadoLibre.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.